drugset / Trial / NCT02903069
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Phase 1
Completed
66 enrolled
Celgene Corporation
Triphase Research and Development III Corp. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the growth of the cancer, reducing the size of the tumor, and/or improving survival. Marizomib (MRZ) is being added to standard-of-care treatments of radiotherapy (RT), temozolomide (TMZ), and Optune.
Timeline
- Start
- 2016-08-17
- Primary completion
- 2021-01-25
- Completion
- 2021-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Marizomib | Small molecule | 0.55 mg/m2 | Intravenous |
| Subject | Marizomib | Small molecule | 1.2 mg/m2 | Intravenous |
| Background | Temozolomide | Small molecule | 75 mg/m2 | — |
| Background | Temozolomide | Small molecule | 150 mg/m2 | — |
| Background | Temozolomide | Small molecule | 200 mg/m2 | — |